BACKGROUND AND PURPOSE: Kinins are pro-inflammatory peptides that are released during tissue injury, including that caused by inflammatory bowel disease. Herein, we assessed the role and underlying mechanisms through which the absence of kinin B(1) receptors exacerbates the development of dextran sulfate sodium (DSS)-induced colitis in mice. EXPERIMENTAL APPROACH: B(1) and B(2) receptor antagonists and B(1) receptor knockout mice (B1(-/-) ) were used to assess the involvement of B(1) and B(2) receptor signalling in a DSS-colitis. B(1) receptor, B(2) receptor, occludin and claudin-4 expression, cytokine levels and cell permeability were evaluated in colon from wild-type (WT) and B1(-/-) mice. KEY RESULTS: DSS-induced colitis was significantly exacerbated in B1(-/-) compared with WT mice. IL-1β, IFN-γ, keratinocyte-derived chemokine and macrophage inflammatory protein-2 were markedly increased in the colon from DSS-treated B1(-/-) compared with DSS-treated WT mice. Treatment of WT mice with a selective B(1) receptor antagonist, DALBK or SSR240612, had no effect on DSS-induced colitis. Of note, B(2) receptor mRNA expression was significantly up-regulated in colonic tissue from the B1(-/-) mice after DSS administration. Moreover, treatment with a selective B(2) receptor antagonist prevented the exacerbation of colitis in B1(-/-) mice following DSS administration. The water- or DSS-treated B1(-/-) mice showed a decrease in occludin gene expression, which was partially prevented by the B(2) receptor antagonist. CONCLUSIONS AND IMPLICATIONS: A loss of B(1) receptors markedly exacerbates the severity of DSS-induced colitis in mice. The increased susceptibility of B1(-/-) may be associated with compensatory overexpression of B(2) receptors, which, in turn, modulates tight junction expression.
BACKGROUND AND PURPOSE: Kinins are pro-inflammatory peptides that are released during tissue injury, including that caused by inflammatory bowel disease. Herein, we assessed the role and underlying mechanisms through which the absence of kinin B(1) receptors exacerbates the development of dextran sulfate sodium (DSS)-induced colitis in mice. EXPERIMENTAL APPROACH: B(1) and B(2) receptor antagonists and B(1) receptor knockout mice (B1(-/-) ) were used to assess the involvement of B(1) and B(2) receptor signalling in a DSS-colitis. B(1) receptor, B(2) receptor, occludin and claudin-4 expression, cytokine levels and cell permeability were evaluated in colon from wild-type (WT) and B1(-/-) mice. KEY RESULTS:DSS-induced colitis was significantly exacerbated in B1(-/-) compared with WT mice. IL-1β, IFN-γ, keratinocyte-derived chemokine and macrophage inflammatory protein-2 were markedly increased in the colon from DSS-treated B1(-/-) compared with DSS-treated WT mice. Treatment of WT mice with a selective B(1) receptor antagonist, DALBK or SSR240612, had no effect on DSS-induced colitis. Of note, B(2) receptor mRNA expression was significantly up-regulated in colonic tissue from the B1(-/-) mice after DSS administration. Moreover, treatment with a selective B(2) receptor antagonist prevented the exacerbation of colitis in B1(-/-) mice following DSS administration. The water- or DSS-treated B1(-/-) mice showed a decrease in occludin gene expression, which was partially prevented by the B(2) receptor antagonist. CONCLUSIONS AND IMPLICATIONS: A loss of B(1) receptors markedly exacerbates the severity of DSS-induced colitis in mice. The increased susceptibility of B1(-/-) may be associated with compensatory overexpression of B(2) receptors, which, in turn, modulates tight junction expression.
Authors: João B Calixto; Rodrigo Medeiros; Elizabeth S Fernandes; Juliano Ferreira; Daniela A Cabrini; Maria M Campos Journal: Br J Pharmacol Date: 2004-11-01 Impact factor: 8.739
Authors: Antoni Stadnicki; Ezbieta Pastucha; Grazyna Nowaczyk; Urszula Mazurek; Danuta Plewka; Grzegorz Machnik; Tadeusz Wilczok; Robert W Colman Journal: Am J Physiol Gastrointest Liver Physiol Date: 2005-03-31 Impact factor: 4.052
Authors: L M Fredrik Leeb-Lundberg; Francois Marceau; Werner Müller-Esterl; Douglas J Pettibone; Bruce L Zuraw Journal: Pharmacol Rev Date: 2005-03 Impact factor: 25.468
Authors: Jiang Xu; Oscar A Carretero; Ying Sun; Edward G Shesely; Nour-Eddine Rhaleb; Yun-He Liu; Tang-Dong Liao; James J Yang; Michael Bader; Xiao-Ping Yang Journal: Hypertension Date: 2005-02-07 Impact factor: 10.190
Authors: Natália Fontana Nicoletti; Jacques Sénécal; Vinicius Duval da Silva; Marcelo R Roxo; Nelson Pires Ferreira; Rafael Leite T de Morais; João Bosco Pesquero; Maria Martha Campos; Réjean Couture; Fernanda Bueno Morrone Journal: Mol Neurobiol Date: 2016-11-16 Impact factor: 5.590
Authors: María José Acuña; Daniela Salas; Adriana Córdova-Casanova; Meilyn Cruz-Soca; Carlos Céspedes; Carlos P Vio; Enrique Brandan Journal: J Cell Commun Signal Date: 2017-12-17 Impact factor: 5.782
Authors: Kelcie A Lahey; Natalie J Ronaghan; Judie Shang; Sébastien P Dion; Antoine Désilets; Richard Leduc; Wallace K MacNaughton Journal: PLoS One Date: 2017-07-03 Impact factor: 3.240